Begin main content

Search

We found 94 result(s)

Intravenous Immunoglobulin for Treatment of Idiopathic Thrombocytopenic Purpura: Economic and Health Service Impact Analyses

Last Updated: September 17, 2008
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Intravenous immunoglobulin (IVIg), a blood product containing pooled IgG immunoglobulins derived from human plasma. Condition Idiopathic thrombocytopenic purpura (ITP) caused by an abnormal immune response that leads to low platelet counts and bleeding. Issue Because of the growing use of IVIg in Canada (including off-label use),...

Octreotide for Endocrine, Oncologic, and Gastrointestinal Disorders: Systematic Review and Budget Impact Analysis

Last Updated: July 21, 2008
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technologies Octreotide, which is a synthetic analogue of somatostatin, inhibits endocrine and exocrine secretions. Condition Octreotide is approved by Health Canada for use in acromegaly, neuroendocrine tumours, pancreatic surgery, and emergency bleeding of gastroesophageal varices. Octreotide is also being used for other unapproved indicati...

Short-Acting Agents for Procedural Sedation and Analgesia in Canadian Emergency Departments: A Review of Clinical Outcomes and Economic Evaluation

Last Updated: March 31, 2008
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Short-acting agents for procedural sedation and analgesia (PSAs) propofol, ketamine HCl, etomidate, and ketamine combined with low-dose propofol (ketofol). Condition Adults who present to emergency departments (EDs) for painful procedures (i.e., treatment for bone fractures, major joint dislocations, cardioversion, and other proced...

Erythropoiesis-Stimulating Agents for Anemia of Chronic Kidney Disease: Systematic Review and Economic Evaluation

Last Updated: March 11, 2008
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Erythropoiesis-stimulating agents (ESA), epoetin alpha (Eprex ®, Janssen-Ortho), darbepoetin (Aranesp ™, Amgen), and epoetin beta (NeoRecormon ®, Roche) Condition Adult patients with anemia of chronic kidney disease (CKD) who need or do not need dialysis. Issue ESAs are routinely used to treat anemia of chronic kidney disease (CK...

Minimally Invasive Arthroplasty in the Management of Hip Arthritic Disease: Systematic Review and Economic Evaluation

Last Updated: February 12, 2008
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Minimally invasive total hip replacement (MI THR) procedures that involve single- and double- incision techniques. Condition Patients who are eligible for THR due to degenerative, rheumatoid, or other arthritic diseases of the hip. Issue Emerging minimally invasive surgical techniques for hip replacement require specialized equip...

Recombinant human growth hormone for Turner syndrome: systematic review and economic evaluation

Last Updated: December 21, 2007
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology and Condition Recombinant human growth hormone (rhGH) for treatment of Turner syndrome (TS). Issue Given the high cost of rhGH treatment and the evolving evidence base for its clinical effect in patients with TS, policy makers need evidence
to inform reimbursement decisions about rhGH. Methods and Results A system...

Thiazide Diuretics as First-Line Treatment for Hypertension: Meta-analysis and Economic Evaluation

Last Updated: December 21, 2007
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology and Condition Thiazide diuretics (TZD) chlorthalidone, hydrochlorothiazide, indapamide, and metolazone for primary hypertension (at least 140 mm Hg systolic or 90 mm Hg diastolic blood pressure). Issue Despite their demonstrated clinical effectiveness and low cost, the rate of first-line TZD use in newly treated hypertensive patien...

Diagnostic Performance and Cost-Effectiveness of Technologies to Measure Bone Mineral Density in Postmenopausal Women

Last Updated: December 4, 2007
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports
Research Type: Devices and Systems

Context and policy issues Osteoporosis is a progressive disease characterized by low bone mass, microarchitectural bone tissue deterioration and loss of bone strength that can lead to an increased risk of fracture. The World Health Organization’s (WHO) definition of osteoporosis is a T score of ≤−2.5, which is equivalent to a hip bone mineral d...

Effectiveness of magnetic resonance imaging (MRI) screening for women at high risk of breast cancer

Last Updated: October 31, 2007
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports
Research Type: Devices and Systems

Context and Policy Issues In 2007, there will be an estimated 22,300 Canadian women diagnosed with breast cancer, and approximately 5,300 deaths. The risk factors for breast cancer include reproductive and hormonal factors, lifestyle factors, a family history of breast cancer, and mutation in the tumour suppression genes BRCA1 or BRCA2. Women ...